---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-22-000059"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2022-10-13T23:59:59+00:00"
generated_at: "2026-06-23T03:47:01.191322+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pacira reports preliminary Q3 2022 revenue of $167.5M, up 31% YoY; EXPAREL sales up 9%

## Summary
- Preliminary unaudited Q3 2022 revenue $167.5M vs $127.7M in Q3 2021.
- EXPAREL net sales $132.6M (Q3 2022) vs $121.9M (Q3 2021); average daily sales 109% of prior year.
- ZILRETTA net sales $26.5M for Q3 2022; iovera° net sales $4.5M.
- Company not providing 2022 revenue or gross margin guidance due to macro uncertainty.
- Monthly intra-quarter revenue disclosure continues; weekly EXPAREL utilization data posted on investor site.

## SEC filing metadata
- accession: 0001396814-22-000059
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2022-10-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681422000059/0001396814-22-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681422000059/pcrx-20221013.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-22-000059
- JSON: https://secwatch.observer/filing/0001396814-22-000059.json
- Plain text: https://secwatch.observer/filing/0001396814-22-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.